Medicinal Product Identification Standards: Consistent, Exchangeable Data
Medicinal product identification is a data-quality and patient-safety concern. Manufacturers, regulators, healthcare providers and digital platforms must exchange product information without losing the meaning of an identifier, substance, dose form or package. A dependable model distinguishes the medicinal product from its attributes, records who assigns each identifier, and preserves relationships when data crosses regulatory, clinical, pharmacy and supply-chain systems.
Overview and business context
The immediate challenge is usually fragmentation: different teams maintain separate records, use different definitions and measure success in different ways. That makes exceptions expensive and weakens confidence in reporting. A useful standards programme starts by defining the objects, activities and outcomes in scope, identifying authoritative sources, and agreeing how compliance or conformance will be demonstrated.
Define the scope, system boundaries and accountable owners before choosing controls.
Use shared terminology and documented criteria so results can be compared across teams.
Keep evidence traceable to the decision, control or requirement it supports.
Review exceptions and changes through an agreed process rather than relying on informal approvals.
What the standards help organisations establish
The referenced documents should be reviewed together as a set of complementary inputs. Their exact requirements, editions and applicability need to be confirmed against the source records and the organisation’s intended use; a title or catalogue identifier alone is not a substitute for reading the normative scope.
ISO 11238:2018 defines data elements and structures for identifying and exchanging regulated information about substances used in medicinal products. It helps distinguish substance identity from product identity and other related attributes, supporting consistent records across regulatory, clinical and supply-chain systems. A reliable implementation should preserve identifiers, relevant substance characteristics, source provenance and relationships to associated product data. This reduces ambiguity when information is exchanged between organisations and supports traceability as substance records are created, maintained, corrected or superseded.
ISO 11240:2012 addresses data elements and structures for identifying and exchanging units of measurement in medicinal-product information. It supports consistent representation of units so that quantity, strength and dose-related values are not silently interpreted differently between systems. Organisations should use controlled unit representations, preserve conversion rules where applicable and validate unit-value combinations at interface boundaries. These practices help reduce ambiguity in exchanged data and make mappings, transformations and corrections easier to trace across healthcare, regulatory and product-information systems.
ISO 11615:2017 specifies data elements and structures for the unique identification and exchange of regulated medicinal-product information. It supports consistent product-level records that can be interpreted across organisations and systems, including when records move between regulatory and healthcare contexts. Implementations should identify which product entity each identifier represents, maintain relationships to relevant package and substance data, and validate attributes that affect matching. Clear mapping and change-control practices help preserve traceability when product information is corrected, expanded or exchanged across markets.
ISO 11616:2017 addresses data elements and structures for the unique identification and exchange of regulated pharmaceutical-product information. It complements broader medicinal-product identification by supporting a consistent representation of pharmaceutical products at the appropriate level of detail. Organisations should preserve relationships between product identifiers and relevant attributes such as substance, strength and dose form, while distinguishing the pharmaceutical product from presentations or packages where required. This helps downstream systems reconcile records reliably and reduces ambiguity in the exchange of regulated product information.
Practical implementation roadmap
Start with a documented baseline rather than assuming that current practice is either wholly compliant or wholly deficient. Identify the processes, systems, people and suppliers in scope; collect a representative sample of records; and map what exists to the outcomes required for medicinal product identification, substances, pharmaceutical product data and cross-system exchange. Separate immediate gaps from long-term improvements. Prioritise by risk, business impact, implementation effort and dependency, and give each selected action a named owner, due date and clear completion criterion.
Pilot the approach with one representative team or service before rolling it out everywhere. Test whether instructions are understandable, whether evidence can be produced without unreasonable manual effort and whether exceptions are routed to someone with authority to resolve them. Use feedback to refine roles, templates and system support. A staged rollout reduces disruption and reveals hidden dependencies early; after launch, schedule a review to confirm that the new practice is being used and that the expected risk or quality improvement is measurable.
Inventory current processes, tools, interfaces and existing evidence.
Perform a gap assessment against the applicable clauses and intended outcomes.
Prioritise gaps by business impact, likelihood, legal obligations and dependency.
Create a control register with owners, evidence requirements and review cadence.
Pilot the approach in a bounded area, test edge cases and refine guidance.
Roll out with training, clear escalation paths and management review.
Monitor performance and update the implementation when requirements or risks change.
Common mistakes to avoid
One mistake is to treat the existence of a policy, template or tool as proof that the underlying control works. Another is to copy a control without adapting it to the actual context, leaving teams with measures that do not reflect how medicinal product identification, substances, pharmaceutical product data and cross-system exchange is used. Avoid choosing metrics before deciding what decision they should support, allowing exceptions to remain open indefinitely or treating incomplete evidence as confirmation. When a gap is found, capture its cause, owner, risk, interim safeguard and verification method; then check whether the remedy prevents recurrence rather than simply closing the record.
Treating a standards checklist as proof that controls work in practice.
Copying a template without adapting it to actual risks and operating conditions.
Using metrics that are easy to collect but do not inform decisions.
Allowing exceptions, mappings or approvals to live only in email or individual knowledge.
Changing systems or procedures without assessing downstream effects and retesting.
Business benefits and how to measure them
Useful measures include the percentage of records with a verified identifier, duplicate and unmatched-record rates, the age of unresolved reconciliation cases, completeness of required attributes and the time needed to propagate an approved correction. Track the result by source system and product class so a good average does not conceal a weak interface.
Choose a small set of measures that managers can act on. Each measure should have a defined calculation, data source, reporting frequency, owner and threshold that prompts investigation. Establish a baseline before introducing a new control, and compare results over enough time to distinguish genuine improvement from normal variation. Include a qualitative review of high-impact exceptions so the dashboard does not obscure important cases behind an attractive average. If a metric changes, record the decision it prompted and later verify whether the action improved the intended outcome.
A well-run programme can improve consistency, reduce avoidable rework, make assurance more efficient and clarify accountability. Measure these outcomes with a small set of indicators: recurring exceptions, unresolved findings, time to complete reviews, evidence completeness, change-related defects and the age of corrective actions. Establish a baseline first and interpret trends alongside changes in scope and risk.
Governance and risk considerations
Maintain a named data owner, a controlled source of reference values, a documented process for identifier assignment and retirement, and an approval path for mappings. For high-risk mismatches, require human review and record the evidence behind the resolution. Confirm the current edition and regulatory applicability of each cited document before treating it as a binding requirement.
Standards should support sound professional judgement, not replace it. Confirm the applicable edition and jurisdiction, preserve a clear audit trail, protect confidential information, and make limitations explicit. Where a standard is used to support a regulatory or contractual claim, have the responsible subject-matter owner verify the precise requirement and evidence before making that claim.
Conclusion
A final readiness check should confirm that the article’s recommendations have been translated into practice: the source requirements are current, relevant owners understand their duties, evidence can be retrieved, exceptions are visible and the review cycle has a real trigger. For medicinal product identification, substances, pharmaceutical product data and cross-system exchange, these checks connect documented standards to day-to-day decisions. Retain a short record of what was adopted, what remains out of scope and what requires further specialist review; revisit it when the context changes.
The strongest implementation connects clear definitions to working controls, meaningful evidence and a feedback loop. Use the four source records as the starting point for a documented applicability review, then translate the relevant requirements into owned procedures and measurable outcomes. This turns standards from a static reference into a repeatable operating capability.
Recommended next steps
Confirm the exact scope and edition of each referenced document.
Name owners for implementation, evidence, review and change approval.
Run a small gap assessment and prioritise the highest-impact risks.
Set measurable acceptance criteria and a recurring review date.
This article is an implementation-oriented overview, not a substitute for the full normative text, legal advice or domain-specific assessment.
Comments